ercutaneous coronary intervention (PCI) for stenosis of the unprotected left main coronary artery (ULMCA) has been recently adopted as a safe and feasible alternative to coronary bypass grafting (CABG) for selected patients, although restenosis is the major problem to be solved. 1-4 Drug-eluting stents (DES) have proven advantages over bare metal stents (BMS) in the prevention of restenosis following PCI, 5, 6 and the use of DES for ULMCA stenosis has shown promising long-term results without an increased risk of stent thrombosis in this particular patient population. 7-10 However, even with DES, rates of target lesion revascularization (TLR) are observed to be higher following PCI for ULMCA stenosis than following CABG. 11 -13 Compared with non-distal ULMCA stenosis, stenosis involving the distal bifurcation area of the ULMCA is reported to be associated with even higher rates of both TLR and major adverse cardiovascular events (MACE). 14 Although several studies have compared the effects of DES and BMS in PCI for ULMCA stenosis, only a few of these observational studies focus on de novo distal ULMCA lesions. [15] [16] [17] [18] Furthermore, because of tremendous baseline demographic and angiographic differences between groups of patients, selection bias may exist in these registries, and the benefit of DES may not be fairly investigated in these observational studies. Indeed, only one prospective randomized control study, in which routine intravascular ultrasound
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(IVUS) guidance and lesion modification with a cutting balloon were performed, compared BMS with paclitaxel-eluting stent for 6-month outcomes in patients following PCI for ULMCA stenosis. 19 In the present study, we used propensity-score matching to justify the probability of exposure to DES. We then used this propensity score-matched cohort to compare BMS with DES for long-term outcomes of PCI for de novo distal ULMCA stenosis and investigated predictors associated with the clinical outcomes following PCI.
Methods

Study Population and Lesion Characteristics
The study retrospectively analyzed patients with diameter stenosis ≥50% of the distal one-third of the ULMCA shaft 20 and who were treated by PCI between December 2000 and November 2009. The Department of Medical Research at Kaohsiung Chang Gung Memorial Hospital approved this retrospective chart review. Patients presenting with acute ST-segment elevation myocardial infarction (MI) or who had previously undergone CABG for coronary artery disease (CAD) were excluded from this study. PCI treatment was chosen in favor of surgery if CABG was considered unsuitable for the patient or if the patient expressed a preference for this treatment and had suitable anatomy for stenting via a percutaneous approach. The patients enrolled for analyses included those undergoing PCI with BMS implantation in the pre-DES era (before December 2003), and the decision of stent type in the post-DES era (after December 2003) was made by the patients and their families instead of doctors because stents were not reimbursed for ULMCA stenosis by National Health Insurance Bureau in Taiwan. To investigate if the differences between the DES and BMS groups were caused by the historical comparison of patients before DES was introduced for PCI, the patients in the BMS group were further divided into groups of pre-DES and post-DES era for analyses.
Lesion Characteristics and Definitions
A diffuseness score and SYNTAX score were used to quantify the extent and severity of coronary atherosclerosis, respectively, as previously described. 21, 22 Lesion length was calculated from the point where stenosis occurred in the ULMCA segment to 5 mm beyond the distal bifurcation if the left anterior descending artery (LAD) or left circumflex artery (LCX) ostium was involved. 4 Hyperlipidemia was defined as serum total cholesterol level >200 mg/dl, and renal insufficiency was defined as serum creatinine >1.4 mg/dl. The European system of cardiac operative risk assessment (EuroSCORE) was used to estimate mortality risk at 30 days. 23 Patients with EuroSCORE of 0-2, 3-5, and ≥6 were classified as low, moderate and high risk, respectively. Patients meeting any of the following criteria were considered unsuitable for CABG: limited life expectancy because of underlying malignancy, age >75 years, or insufficiently stable condition according to the surgeon's evaluation. The main techniques of stent deployment for bifurcation lesions were those described by Iakovou et al. 24 Revascularization was considered complete when all vessels >1.5 mm in diameter with diameter stenosis ≥50% were treated. 25 Angiographic success was defined as revascularization in the target lesion with grade 3 Thrombolysis In Myocardial Infarction flow (TIMI) and residual diameter stenosis <30% on angiography. Procedural success was defined as angiographic success without procedure-related death, Q-wave MI, stroke, repeat PCI, or emergency CABG during hospitalization.
Study Endpoints
Study endpoints in this study included in-hospital outcome, TLR and long-term MACE following the index PCI. Analyzed in-hospital outcomes included post-PCI MI, repeat revascularization, acute or subacute stent thrombosis, stroke, pulmonary edema, ventricular tachyarrhythmia, and death. Death was classified as either cardiac or non-cardiac, with death from an unknown cause considered to be cardiacrelated. Post-PCI MI was defined as an increase in cardiac troponin I or creatinine kinase MB >20%. 26 Clinical followup was scheduled for all patients, and angiographic followup was arranged for patients with symptoms indicating myocardial ischemia and was routinely performed whenever possible at 6-12 months after PCI. Regardless of the patient's symptoms, we performed repeat PCI or CABG when a follow-up angiogram showed a significant restenosis (>50% diameter stenosis) between the ULMCA ostium and the distal stent edge or 5 mm distal to the bifurcation area if the LCX ostium or LAD ostium was left uncovered by the stent. TLR was defined as requiring revascularization for restenosis in the previously treated segment. 7 Definite early stent thrombosis was defined as acute coronary syndrome with angiographic conformation of thrombus or occlusion after PCI, and probable early stent thrombosis was defined as unexplained death, target vessel MI without angiographic confirmation or other identified culprit lesions after PCI, according to the criteria proposed by the Academic Research Consortium. 27 Stent thrombosis was further classified as acute (<24 h), subacute (1-30 days) or chronic (1-12 months). MACE comprised stent thrombosis, MI, and cardiac death. Long-term outcomes included TLR, all revascularizations, stent thrombosis, MI, cardiac death, all-cause death and MACE with or without TLR during follow-up.
Statistical Analysis
Data are expressed as means ± standard deviation (SD) for continuous variables and as frequencies for categorical variables. Differences between groups in the original cohort were assessed by chi-square test for categorical variables and t-test for continuous variables.
To account for the selection bias of stent type, we calculated propensity scores predicting conditional probabilities for receiving DES in each patient. The covariates that were adjusted for exposure to DES included age, sex, body weight, diabetes mellitus (DM), renal insufficiency, prior PCI, left ventricular ejection fraction (LVEF) <40%, significant heart failure (HF) of New York Heart Association functional class (NYHA) III/IV, non ST-segment elevation MI (NSTEMI) upon admission, SYNTAX score, EuroSCORE, multivessel disease, LAD occlusion, LCX occlusion, reference vessel diameter (RVD) before PCI, diffuseness score, IVUS guidance, implantation of 2 stents, stent crossing the distal ULMCA bifurcation, final kissing-balloon technique, ad hoc PCI, and complete revascularization.
The distributions of revascularization-, TLR-, cardiac death-and MACE-free survival during the follow-up period were estimated by Kaplan-Meier method, and intergroup differences were compared by log rank test in the propensity score-matched cohort. Cox hazard proportion regression model was used to estimate the hazard ratio for long-term outcomes during follow-up. Covariates controlled for confounding effect included propensity score, age, EuroSCORE, SYNTAX score, body weight, diffuseness score, RVD, DES (vs. BMS), sex, DM, renal insufficiency, IVUS guidance, NSTEMI upon admission, multivessel disease, significant HSUEH SK et al. These data suggest patients in the BMS group had a higher risk than those in the DES group. Although both groups had similar diffuseness and SYNTAX scores, the baseline angiographic data showed that the RVD was significantly different before PCI, and was larger in the BMS group than in the DES group (3.80±0.67 vs. 3.52±0.63, P=0.010), and the mean stent width was also higher in the BMS group (3.66±0.4 vs. 3.34±0.2, P<0.010). Furthermore, the patients in the DES group were more likely to undergo a complex stenting strategy with implantation of 2 stents (41.7% vs. 11.8%, P<0.001), and the mean stent length in the DES group was significantly longer than that in the BMS group (26.2±6.1 vs. 21.2±8.2, P<0.001). There was also a trend for BMS to be less likely to be implanted across the distal LMCA bifurcation than DES (82.4% vs. 92.1%, P=0.056). These results indicate the angiographic characteristics and applied PCI technique differed between the 2 groups.
Because of the selection bias in these 2 groups, we performed an analysis of the propensity score-matched cohort after adjusting for the probability of receiving DES for ULMCA stenosis, and the characteristics of the matched cohort are listed in Table 1 . After matching, no significant difference was noted between the 2 groups for each parameter, except stent width (P=0.002) and length (P=0.082), which were considered to be related to stent type.
To investigate if the differences between the 2 groups were caused by historical comparison, the patients in the BMS group was categorized into pre-DES and post DES era groups and the results of subgroup analyses are listed on Table 2 . Surprisingly, both the BMS groups in the pre-DES era and the DES group were similar in terms of age and SYNTAX score and in the incidences of DM, NYHA III/IV, and EuroSCORE ≥6, and the BMS group in the post-DES era had a significantly higher percentage of EuroSCORE ≥6 (76.7%, P=0.041). Furthermore, there was a trend for patients in the BMS group in the post-DES era to more frequently present with significant HF (30.0%, P=0.057). Although statistically insignificant, the age of the BMS patient group in the pre-DES era was younger than that for the group in the post-DES era. Additionally, in 
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the post-DES era, the DES penetration rate in patients with NYHA I/II was 84%, whereas it was only 55.4% of those with NYHA III/IV who received a DES. Approximately 90% of the patients with EuroSCORE 1-5 received DES, but only 74.4% of those with EuroSCORE ≥6 received DES. These results suggested that patients with a higher risk or older age were more likely to undergo BMS implantation to treat UMLCA stenosis, even in the post-DES era, and that the overall severity and extent of CAD were not associated with the selection of stent type for this particular lesion. Table 3 shows the in-hospital outcomes of the propensity score-matched cohort after stenting for ULMCA stenosis; 4 patients in the DES group developed post-PCI MI, and 3 patients in the BMS group had this complication (11.4% vs. 8.6%, P=1.000). One patient in the BMS group had probable acute stent thrombosis, presenting as acute pulmonary edema, ventricular fibrillation and ST elevation in the precordial leads on ECG. This patient died before emergency revascularization could be performed and was the only death in the propensity score-matched cohort during hospitalization.
To understand the effect of stent type on long-term outcome, we performed survival analysis by Kaplan-Meier estimate in the propensity score-matched cohort, and the results are shown in Figure 1 . Including the acute thrombosis event, the BMS group had a total of 2 events of probable stent thrombosis with subsequent cardiac death, whereas stent thrombosis was not noted in the DES group. Most MACE observed in the DES group were related to TLR. As compared with the BMS group, TLR-free survival and MACEfree survival when TLR was included were significantly higher in the DES group. The TLR-free survival at 3 years was 96.2% and 58% in the DES and BMS groups, respectively (P<0.001). The MACE-free survival (including TLR) at 3 years was 91.3% and 57.0% in the DES and BMS groups, respectively (P<0.001). These analyses demonstrate that DES is associated with better clinical outcomes than BMS in the prevention of TLR at the distal bifurcation of the ULMCA.
We were also interested in the factors associated with long-term outcomes and analyzed outcome parameters by using a Cox hazard proportion regress model ( Table 4) . Diffuseness score correlated with an increased risk of all revascularizations during follow-up (hazard ratio (HR) 1.228; 95%CI 1.067-1.412), whereas propensity score standing for the probability of receiving DES was negatively proportional to the overall revascularization risk (HR 0.096; 95%CI 0.014-0.678). Implantation of DES significantly predicted fewer TLR events (HR 0.061; 95%CI 0.008-0.486), and significant HF of NYHA III/IV was associated with a higher TLR rate (HR 5.780; 95%CI 1.550-21.739). When stents were deployed across the distal ULMCA bifurcation, TLR was less likely to occur (HR 0.136; 95%CI 0.025-0.743). For the prediction of MACE, including TLR, NYHA III/IV (HR 6.849; 95%CI 2.000-23.256) and age (HR 1.058; 95%CI 1.007-1.111) were independent predictors, whereas DES was negatively associated with this outcome parameter (HR 0.116; 95%CI 0.026-0.516).
Because both implantation of DES and significant HF (NYHA III/IV) were independently associated with TLR and MACE, we then stratified the entire cohort of 178 patients by these 2 parameters (DES vs. BMS and NYHA III/IV vs. NYHA I/II or no HF) to investigate if implantation of DES in patients with significant HF (NYHA III/IV) was associated with better clinical outcomes than with BMS, and the results are outlined in Figure 2 . Compared with the BMS group with significant HF, the DES group with significant A B Figure 2 . Kaplan-Meier survival estimates of entire patient cohort stratified by stent type and significant heart failure. The TLR-free (A) and MACE-free (B) survival estimates for the entire patient cohort are stratified by stent type and significant heart failure (HF). Significant HF indicates NYHA III/IV. *P value of paired comparison by log rank test is <0.05 as compared with BMS with significant HF. # P value is <0.05 as compared with DES with significant HF. BMS, bare metal stent; DES, drug-eluting stent; MACE, major adverse cardiovascular events; NYHA, New York Heart Association function class; TLR, target lesion revascularization. HSUEH SK et al.
HF had significantly higher TLR-free survival at 3 years (90.9% vs. 55.6%; P=0.046). Furthermore, significant HF was associated with significantly lower MACE-free survival (including TLR) in both the DES and BMS groups. These analyses suggest that implantation of DES for distal ULMCA stenosis in high-risk patients with significant HF is associated with lower rates of TLR and MACE than with BMS.
Discussion
This investigation revealed that implantation of DES for distal ULMCA stenosis is associated with less TLR and MACE than with BMS, leading to favorable long-term outcomes, excepting MI or cardiac death. Significant HF of NYHA III-IV was an independent predictor of TLR and MACE after a coronary stenting procedure for distal ULMCA stenosis.
Patient Selection Bias With Different Stent Types
As with previous observational registries of clinical outcomes following PCI for ULMCA stenosis, 10,28,29 the patients in the DES or BMS group in the present study differed in their baseline demographics, angiographic characteristics and even in the PCI procedure used for the coronary lesions. Similar to the GISE-SICI registry, 17 patients who had undergone BMS implantation in the current study had a higher EuroSCORE and larger RVD than those in the DES group. In contrast, in the MAIN-COMPARE registry, a higher percentage of patients in the DES group had DM, triple-vessel disease and advanced age than those in the BMS group. 16 These baseline differences before PCI may not only affect the subsequent PCI procedure chosen for managing the lesions in the coronary artery but also potentially alter the clinical outcomes after coronary stenting for ULMCA stenosis. A randomized control trial or a propensity score-matched study is necessary to fairly justify the clinical benefit and risk of stent type to avoid the selection bias caused by either patient or physician preference.
Explanation for BMS Preference in High-Risk Patients
Our study indicates that high risk patients have a higher chance of undergoing BMS implantation for distal ULMCA stenosis. Although our current analyses may not provide the cause of this unusual phenomenon, several issues should be taken into consideration. According to the currently available guidelines for PCI, CABG remains the treatment of choice for ULMCA stenosis, 2 and in Taiwan neither BMS nor DES is reimbursed by the National Health Insurance for the treatment of ULMCA stenosis. Moreover, despite fewer TLR following PCI in many studies, the DES has not proven its superiority over BMS in lowering the mortality rate. 11 Additionally, 1-year treatment with clopidogrel was not advised in some of the present high-risk patients because of preprocedural bleeding complications, planned surgery soon after PCI, or other contraindications because of the patient's underlying medical condition. Given that the very old age of the patients who received a BMS in the post-DES era, patients and their families might have chosen the less invasive and less expensive treatment strategy of PCI using a BMS when CABG was considered extremely high risk or the patient refused CABG.
Baseline Angiographic Features and the Selection of Stent and Stent Deployment
A previous study has shown that the minimal stent area with a BMS should be larger than that with a DES to avoid restenosis. 30 Furthermore, it is reported that the minimal stent area of a BMS should achieve at least 9 mm 2 in order to reduce the TLR rate following PCI for ULMCA stenosis to less than 5%. 31 Although the extent and severity of coronary atherosclerosis were not associated with the selection of stent type in the present study, the patients that underwent BMS implantation had significantly higher RVD than those in the DES group, suggesting that RVD may potentially influence the selection of stent. After adjustment for RVD, the stent width was significantly greater in the BMS group in the propensity score-matched cohort, suggesting that once a BMS was chosen, a larger stent diameter was preferred to achieve a larger stent area in order to avoid subsequent restenosis following PCI. In contrast, a longer stent is preferred to cover more of the atheromatous area when a DES was selected because, unlike the BMS, stent length is not associated with increased in-stent restenosis. 32, 33 Another important finding in our study is that stent not being deployed across the bifurcation area is associated with an increased risk of TLR. Compared with non-distal ULMCA stenosis, previous studies show increased restenosis of distal ULMCA lesions, even in patients undergoing DES implantation, 14,34 and the restenotic area usually occurred at the ostia of LCX or LAD instead of that of the ULMCA per se. 35 To avoid injury during stent deployment, in some cases the operator may spare the LAD and LCX ostial areas in type 4 bifurcation lesions of the Lefevre classification, 36 in which both the LCX and LAD ostia have no significant stenosis. However, the protrusion of the edge of the stent into the LAD or LCX ostium may occur and cause subsequent restenosis of either the LCX or LAD ostium. Our study suggests that stents should be placed across the bifurcation area in order to avoid restenosis, regardless of the type of bifurcation lesion.
HF and Outcomes Following PCI for Distal ULMCA Stenosis
An interesting finding in this study is that significant HF (NYHA III/IV) is an independent predictor for TLR in multivariate analysis. Although previous studies have shown that HF is associated with more cardiac death in patients after coronary stenting, 37 and a lower LVEF predicts MACE after PCI for ULMCA stenosis, 38 HF is never shown to associate with more TLR. Multiple analyses in this retrospective study having a small number of events may increase the chance of false-positive findings, and a wide range of confidence interval may suggest this possibility. However, in our study, approximately 60% of patients have multivessel disease, and more than one-third had undergone PCI for other coronary lesions before this index procedure. Indeed, our patient population carried a high risk based on the estimated EuroSCORE, indicating that patients with distal ULMCA stenosis are at the far end of the cardiovascular disease continuum. 39 Significant HF not only demonstrates poor left ventricular function reserve but also implies a severe inflammation response in patients with diffuse atherosclerosis. 40-42 Furthermore, one study has shown that the serum level of high-sensitivity C-reactive protein may independently predict 9-month mortality following after PCI for ULMCA stenosis. 43 Therefore, the association between TLR and significant HF needs to be verified in a large-scale study.
Implications for Clinical Practice
As in previous studies, the current analytical results indicate that implantation of DES for ULMCA stenosis is associated with lower TLR and MACE rates than with BMS. Given its similar peri-procedural mortality and stent thrombosis rates
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in comparison with BMS, DES should be considered the preferred stent type for this specific patient population if PCI is chosen in favor of CABG and dual antiplatelet therapy can be expected to be used for at least 1 year. In this study, advanced age and significant HF independently predicted TLR and MACE after revascularization procedure. For patients of an advanced age or with significant HF in whom restenosis in the bifurcation area of the ULMCA may cause severe complications, implantation of a DES is strongly recommended. Additionally, the stent, either DES or BMS, should be implanted across the bifurcation, even when single-stent strategy is chosen in patients in whom significant stenosis of the LAD or LAD ostium is initially not noted.
Study Limitations
The major limitation of this study is its small case number and that all patients were treated at a single institution. Furthermore, a selection bias of stent type exists in this retrospective study. Additionally, we did not sophisticatedly analyze the data from follow-up angiography performed at 6 months following coronary stenting, so the pattern of restenosis at the distal bifurcation area of ULMCA is unclear. Nevertheless, given its similar nature to randomization, this long-term, propensity score matched-cohort study is still helpful when attempting to understand the outcomes of PCI with either DES or BMS for distal ULMCA stenosis.
Conclusions
This propensity score-matched cohort study showed lower TLR and MACE rates in patients following PCI with DES implantation than with BMS for de novo distal ULMCA stenosis, but MI and cardiac death did not significantly differ between the 2 groups. Significant HF may increase the risks of TLR and MACE in this particular patient group, and implantation of DES in these patients was associated with fewer TLR and MACE. When PCI is chosen to manage distal ULMCA stenosis, DES is the preferred type of stent in the absence of contraindications.
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